2018

Sok D, Burton, DR. (2018) Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 19(11):1179-1188.

Cao L, Pauthner M, Andrabi R, Rantalainen K, Berndsen Z, Diedrich JK, Menis S, Sok D, Bastidas R, Park SR, Delahunty CM, He L, Guenaga J, Wyatt RT, Schief WR, Ward AB, Yates JR 3rd, Burton DR, Paulson JC. (2018) Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. Nat Commun 9(1):3693.

Bianchi M, Turner HL, Nogal B, Cottrell CA, Oyen D, Pauthner M, Bastidas R, Nedellec R, McCoy LE, Wilson IA, Burton DR, Ward AB, Hangartner L. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity. 49(2):288-300.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium. Systematic analysis of monoclonal antibodies against Ebola Virus GP defines features that contribute to protection. Cell. 174(4):938-952.

Khan SN, Sok D, Tran K, Movsesyan A, Dubrovskaya V, Burton DR, Wyatt RT. (2018) Targeting the HIV-1 spike and coreceptor with Bi- and Trispecific antibodies for single-component broad inhibition of entry. J Virol. 92(18):e00384-18

Ali A, Ng HL, Blankson JN, Burton DR, Buckheit RW, Moldt B, Fulcher JA, Ibarrondo FJ, Anton PA, Yang OO. (2018) Highly attenuated infection with a Vpr-deleted molecular clone of HIV-1. J Infect Dis. 218(9):1447-1452.

Martins MA, Tully DC, Pedreño-Lopez N, von Bredow B, Pauthner MG, Shin YC, Yuan M, Lima NS, Bean DJ, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Magnani DM, Ricciardi MJ, Bailey VK, Altman JD, Burton DR, Ejima K, Allison DB, Evans DT, Rakasz EG, Parks CL, Bonaldo MC, Capuano S 3rd, Lifson JD, Desrosiers RC, Allen TM, Watkins DI. (2018) Mamu-B*17+ rhesus macaques vaccinated with env, vif, and nef manifest early control of SIVmac239 replication. J Virol. 92(16):e00690-18.

Andrabi R, Bhiman JN, Burton DR. (2018) Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 53:143-151.

Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC. (2018) Global site-specific analysis of glycoprotein N-glycan processing. Nat Protoc. 13(6):1196-1212.

Magnani DM, Rogers TF, Maness NJ, Grubaugh ND, Beutler N, Bailey VK, Gonzalez-Nieto L, Gutman MJ, Pedreño-Lopez N, Kwal JM, Ricciardi MJ, Myers TA, Julander JG, Bohm RP, Gilbert MH, Schiro F, Aye PP, Blair RV, Martins MA, Falkenstein KP, Kaur A, Curry CL, Kallas EG, Desrosiers RC, Goldschmidt-Clermont PJ, Whitehead SS, Andersen KG, Bonaldo MC, Lackner AA, Panganiban AT, Burton DR, Watkins DI. (2018) Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. Nat Commun. 9(1):1624

Shivatare VS, Shivatare SS, Lee CD, Liang CH, Liao KS, Cheng YY, Saidachary G, Wu CY, Lin NH, Kwong PD, Burton DR, Wu CY, Wong CH. (2018) Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies. J Am Chem Soc. 140(15):5202-5210.

Walker LM, Burton DR. (2018) Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat Rev Immunol. 18(5):297-308

Zhou T, Zheng A, Baxa U, Chuang GY, Georgiev IS, Kong R, O’Dell S, Shahzad-Ul-Hussan S, Shen CH, Tsybovsky Y, Bailer RT, Gift SK, Louder MK, McKee K, Rawi R, Stevenson CH, Stewart-Jones GBE, Taft JD, Waltari E, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CD, Wu CY; NISC Comparative Sequencing Program, Mullikin JC, Bewley CA, Burton DR, Polonis VR, Shapiro L, Wong CH, Mascola JR, Kwong PD, Wu X. (2018) A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity. 48(3):500-513.

Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Hedestam GBK, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME. (2018) Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight. 3(5):pii:97018.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B. (2018) Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 14(3):e1006860.

Teijaro JR, Burton DR. (2018) Taking down defenses to improve vaccines. Science. 359(6373):277-278.